(VIANEWS) - Repligen Corporation (RGEN), Avid Bioservices (CDMO), Huron Consulting Group (HURN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Repligen Corporation (RGEN)
37.7% sales growth and 7.82% return on equity
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
Repligen Corporation's sales growth this year is expected to be 22.3% and 15% for next year.
Year-on-year quarterly revenue growth grew by 71.7%, now sitting on 670.53M for the twelve trailing months.
Volume
Today's last reported volume for Repligen Corporation is 246382 which is 44.55% below its average volume of 444366.
Repligen Corporation's sales growth for the next quarter is 37.7%. The company's growth estimates for the ongoing quarter and the next is 5.9% and negative -1.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.82%.
Volatility
Repligen Corporation's last day, last week, and last month's current intraday variation average was 0.49%, 2.80%, and 2.09%, respectively.
Repligen Corporation's highest amplitude of average volatility was 3.28% (day), 6.20% (last week), and 4.97% (last month), respectively.
Repligen Corporation's Stock Yearly Top and Bottom Value
Repligen Corporation's stock is valued at $195.01 at 05:22 EST, way below its 52-week high of $327.32 and way higher than its 52-week low of $162.29.
Repligen Corporation's Moving Average
Repligen Corporation's value is under its 50-day moving average of $209.69 and way below its 200-day moving average of $237.32.2. Avid Bioservices (CDMO)
20.7% sales growth and 27.91% return on equity
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture.
Avid Bioservices's sales growth this year is anticipated to be 22.8% and 28.4% for next year.
Year-on-year quarterly revenue growth grew by 24%, now sitting on 106.28M for the twelve trailing months.
Volume
Today's last reported volume for Avid Bioservices is 486565 which is 28.63% below its average volume of 681817.
Avid Bioservices's sales growth is a negative 0% for the present quarter and 20.7% for the next. The company's growth estimates for the ongoing quarter and the next is 300% and 275%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.91%.
Volatility
Avid Bioservices's last day, last week, and last month's current intraday variation average was 2.38%, 2.31%, and 2.88%, respectively.
Avid Bioservices's highest amplitude of average volatility was 4.12% (day), 5.00% (last week), and 6.40% (last month), respectively.
Avid Bioservices's Stock Yearly Top and Bottom Value
Avid Bioservices's stock is valued at $21.50 at 05:22 EST, way under its 52-week high of $34.51 and way above its 52-week low of $15.22.
Avid Bioservices's Moving Average
Avid Bioservices's worth is under its 50-day moving average of $23.27 and way under its 200-day moving average of $24.58.3. Huron Consulting Group (HURN)
14.5% sales growth and 4.74% return on equity
Huron Consulting Group Inc., a professional services firm, provides consultancy services in the United States and internationally.
Huron Consulting Group's sales growth this year is expected to be 5.8% and 8% for next year.
Year-on-year quarterly revenue growth grew by 9.1%, now sitting on 855.69M for the twelve trailing months.
Volume
Today's last reported volume for Huron Consulting Group is 164527 which is 29.08% above its average volume of 127461.
Huron Consulting Group's sales growth for the next quarter is 14.5%. The company's growth estimates for the current quarter and the next is 73.3% and 45.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.74%.
Volatility
Huron Consulting Group's last day, last week, and last month's current intraday variation average was 2.30%, 1.19%, and 1.13%, respectively.
Huron Consulting Group's highest amplitude of average volatility was 3.28% (day), 3.17% (last week), and 3.05% (last month), respectively.
Huron Consulting Group's Stock Yearly Top and Bottom Value
Huron Consulting Group's stock is valued at $49.33 at 05:22 EST, way under its 52-week high of $59.09 and way above its 52-week low of $42.66.
Huron Consulting Group's Moving Average
Huron Consulting Group's worth is above its 50-day moving average of $46.88 and above its 200-day moving average of $49.31.4. Pinnacle Financial Partners (PNFP)
14.2% sales growth and 10.32% return on equity
Pinnacle Financial Partners, Inc., together with its subsidiaries, operates as the bank holding company for Pinnacle Bank that provides various banking products and services in the United States.
Pinnacle Financial Partners's sales growth this year is anticipated to be 21.9% and 11.6% for next year.
Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 1.31B for the twelve trailing months.
Volume
Today's last reported volume for Pinnacle Financial Partners is 605405 which is 32.01% above its average volume of 458603.
Pinnacle Financial Partners's sales growth for the next quarter is 14.2%. The company's growth estimates for the current quarter and the next is a negative 1.2% and negative -3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.32%.
Volatility
Pinnacle Financial Partners's last day, last week, and last month's current intraday variation average was 6.40%, 3.31%, and 1.86%, respectively.
Pinnacle Financial Partners's highest amplitude of average volatility was 6.53% (day), 4.92% (last week), and 3.37% (last month), respectively.
Pinnacle Financial Partners's Stock Yearly Top and Bottom Value
Pinnacle Financial Partners's stock is valued at $95.00 at 05:22 EST, way under its 52-week high of $111.31 and way higher than its 52-week low of $81.65.
Pinnacle Financial Partners's Moving Average
Pinnacle Financial Partners's worth is under its 50-day moving average of $99.36 and below its 200-day moving average of $95.22.5. U.S. Physical Therapy (USPH)
13.9% sales growth and 13.43% return on equity
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.
U.S. Physical Therapy's sales growth this year is anticipated to be 16.7% and 10.8% for next year.
Year-on-year quarterly revenue growth grew by 10.5%, now sitting on 489.72M for the twelve trailing months.
Volume
Today's last reported volume for U.S. Physical Therapy is 103849 which is 3.99% below its average volume of 108173.
U.S. Physical Therapy's sales growth for the next quarter is 13.9%. The company's growth estimates for the current quarter and the next is a negative 18.8% and 3.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.43%.
Volatility
U.S. Physical Therapy's last day, last week, and last month's current intraday variation average was 2.76%, 3.18%, and 1.63%, respectively.
U.S. Physical Therapy's highest amplitude of average volatility was 4.16% (day), 4.14% (last week), and 2.88% (last month), respectively.
U.S. Physical Therapy's Stock Yearly Top and Bottom Value
U.S. Physical Therapy's stock is valued at $91.06 at 05:22 EST, way below its 52-week high of $123.38 and higher than its 52-week low of $84.43.
U.S. Physical Therapy's Moving Average
U.S. Physical Therapy's worth is under its 50-day moving average of $95.69 and way below its 200-day moving average of $106.73.6. Kennametal (KMT)
6.4% sales growth and 9.68% return on equity
Kennametal Inc. develops and applies tungsten carbides, ceramics, and super-hard materials and solutions for use in metal cutting and extreme wear applications to enable customers work against corrosion and high temperatures conditions worldwide.
Kennametal's sales growth this year is expected to be 10.4% and 6.8% for next year.
Year-on-year quarterly revenue growth grew by 10.5%, now sitting on 1.97B for the twelve trailing months.
Volume
Today's last reported volume for Kennametal is 557900 which is 3.42% above its average volume of 539411.
Kennametal's sales growth is a negative 0% for the current quarter and 6.4% for the next. The company's growth estimates for the present quarter and the next is 40.6% and 15.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.68%.
Volatility
Kennametal's last day, last week, and last month's current intraday variation average was 2.55%, 2.13%, and 1.87%, respectively.
Kennametal's highest amplitude of average volatility was 3.84% (day), 2.32% (last week), and 3.62% (last month), respectively.
Kennametal's Stock Yearly Top and Bottom Value
Kennametal's stock is valued at $32.01 at 05:22 EST, way under its 52-week high of $43.04 and higher than its 52-week low of $31.62.
Kennametal's Moving Average
Kennametal's worth is below its 50-day moving average of $35.14 and way below its 200-day moving average of $36.46.7. Ameren (AEE)
5.9% sales growth and 10.4% return on equity
Ameren's sales growth this year is anticipated to be 6.1% and 4.4% for next year.
Year-on-year quarterly revenue growth grew by 5.5%, now sitting on 5.74B for the twelve trailing months.
Volume
Today's last reported volume for Ameren is 908527 which is 28.73% below its average volume of 1274800.
Ameren's sales growth for the next quarter is 5.9%. The company's growth estimates for the ongoing quarter and the next is 8.8% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.4%.
Volatility
Ameren's last day, last week, and last month's current intraday variation average was 1.52%, 1.45%, and 0.98%, respectively.
Ameren's highest amplitude of average volatility was 1.66% (day), 1.94% (last week), and 1.97% (last month), respectively.
Ameren's Stock Yearly Top and Bottom Value
Ameren's stock is valued at $87.30 at 05:22 EST, under its 52-week high of $90.77 and way above its 52-week low of $69.79.